Stockysis — AI-Powered Stock News & Sentiment Analysis

Oppenheimer Maintains Outperform on CalciMedica, Lowers Price Target to $10

Benzinga Newsdesk www.benzinga.com Negative 85.1%

Neg 85.1% Neu 0% Pos 0%

Oppenheimer analyst Leland Gershell maintains CalciMedica (NASDAQ:CALC) with a Outperform and lowers the price target from $20 to $10.

Comments

No comments yet. Be the first!